Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQ: TNXP · Real-Time Price · USD
19.19
+0.36 (1.91%)
At close: May 12, 2025, 4:00 PM
19.19
0.00 (0.00%)
After-hours: May 12, 2025, 7:59 PM EDT
TNXP Revenue
In the year 2024, Tonix Pharmaceuticals Holding had annual revenue of $10.09M with 29.94% growth. Tonix Pharmaceuticals Holding had revenue of $2.58M in the quarter ending December 31, 2024, a decrease of -31.68%.
Revenue (ttm)
$10.09M
Revenue Growth
+29.94%
P/S Ratio
1.40
Revenue / Employee
$124,617
Employees
81
Market Cap
123.49M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
TNXP News
- 6 hours ago - Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights - GlobeNewsWire
- 13 days ago - Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting - GlobeNewsWire
- 18 days ago - Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025 - GlobeNewsWire
- 26 days ago - Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025 - GlobeNewsWire
- 4 weeks ago - Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix's Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana's Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies - GlobeNewsWire
- 5 weeks ago - Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting - GlobeNewsWire
- 5 weeks ago - Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference - GlobeNewsWire
- 5 weeks ago - Tonix Pharmaceuticals Launches TONIX ONE™, a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition - GlobeNewsWire